… REGEN-COV program, we hypothesized that a combination of neutralizing, noncompeting
monoclonal antibodies could have activity in both treatment and prevention of SARS-CoV-2 …

… of symptoms with subcutaneous REGEN-COV for participants … no participants receiving
subcutaneous REGEN-COV had these … REGEN-COV. Overall, these results demonstrate that …

… (previously known as REGN-COV2), a combination of the monoclonal antibodies …
subcutaneous REGEN-COV prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

… The objective of this study was to describe an innovative service and evaluate the safety
of administering REGEN-COV, a monoclonal antibody combination of casirivimab and …

… the SARS-CoV-2 spike protein receptor–binding domain and block virus entry. The 2-antibody
combination reduces the risk of emergence of treatment-induced SARS-CoV-2 variants …

… characterisation of the clinical effects of REGEN-COV. Moreover, identifying a … of REGEN-COV
in the setting of a global pandemic. A 1200 mg subcutaneous (SC) dose of REGEN-COV …

… Green dashed line: cumulative number of REGEN-Cov administrations. Red line: cumulative
number of COVID-19 infections among patients treated with REGEN-Cov in our cohort. …

… In this retrospective analysis of immunodeficient patients granted REGEN-COV under
emergency compassionate use, REGEN-COV treatment was associated with rapid viral clearance …

… antibody combination casirivimab and imdevimab (REGEN-COVTM) administered
subcutaneously (SC) prevented symptomatic SARS-CoV-… same household as a SARS-CoV-2-infected …

… REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has
been approved as a treatment for high-risk patients infected with SARS-CoV… of REGEN-COV …